Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors

por Benes, Cyril H
Publicado 2015

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

por Benes, Cyril, Settleman, Jeff
Publicado 2009

TP53 mutation status: emerging biomarker for precision radiation medicine?

por Willers, Henning, Wang, Meng, Benes, Cyril H.
Publicado 2018

Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets

por Amzallag, Arnaud, Ramaswamy, Sridhar, Benes, Cyril H.
Publicado 2019

Detection of Dysregulated Protein Association Networks by High-Throughput Proteomics Predicts Cancer Vulnerabilities

por Lapek, John D., Greninger, Patricia, Morris, Robert, Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Benes, Cyril H., Haas, Wilhelm
Publicado 2017

Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties

por Menden, Michael P., Iorio, Francesco, Garnett, Mathew, McDermott, Ultan, Benes, Cyril H., Ballester, Pedro J., Saez-Rodriguez, Julio
Publicado 2013

Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin

por Yoo, Byunghee, Greninger, Patricia, Stein, Giovanna T., Egan, Regina K., McClanaghan, Joseph, Moore, Anna, Benes, Cyril H., Medarova, Zdravka
Publicado 2018

Alginate-based 3D cancer cell culture for therapeutic response modeling

por Davoudi, Farideh, Ghorbanpoor, Samar, Yoda, Satoshi, Pan, Xiao, Crowther, Giovanna Stein, Yin, Xunqin, Murchie, Ellen, Hata, Aaron N., Willers, Henning, Benes, Cyril H.
Publicado 2021

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

por Chen, Li, Stuart, Lynda, Ohsumi, Toshiro K, Burgess, Shawn, Varshney, Gaurav K, Dastur, Anahita, Borowsky, Mark, Benes, Cyril, Lacy-Hulbert, Adam, Schmidt, Emmett V
Publicado 2013

Predicting and affecting response to cancer therapy based on pathway-level biomarkers

por Ben-Hamo, Rotem, Jacob Berger, Adi, Gavert, Nancy, Miller, Mendy, Pines, Guy, Oren, Roni, Pikarsky, Eli, Benes, Cyril H., Neuman, Tzahi, Zwang, Yaara, Efroni, Sol, Getz, Gad, Straussman, Ravid
Publicado 2020

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

por Lev, Avital, Lulla, Amriti R., Wagner, Jessica, Ralff, Marie D., Kiehl, Joshua B., Zhou, Yan, Benes, Cyril H., Prabhu, Varun V., Oster, Wolfgang, Astsaturov, Igor, Dicker, David T., El-Deiry, Wafik S.
Publicado 2017

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer

por Najafov, Ayaz, Zervantonakis, Ioannis K., Mookhtiar, Adnan K., Greninger, Patricia, March, Ryan J., Egan, Regina K., Luu, Hoang Son, Stover, Daniel G., Matulonis, Ursula A., Benes, Cyril H., Yuan, Junying
Publicado 2018

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

por Gill, Sonja J., Travers, Jon, Pshenichnaya, Irina, Kogera, Fiona A., Barthorpe, Syd, Mironenko, Tatiana, Richardson, Laura, Benes, Cyril H., Stratton, Michael R., McDermott, Ultan, Jackson, Stephen P., Garnett, Mathew J.
Publicado 2015

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors

por Ducker, Gregory S., Atreya, Chloe E., Simko, Jeffry P., Hom, Yun K., Matli, Mary R., Benes, Cyril H., Hann, Byron, Nakakura, Eric K., Bergsland, Emily K., Donner, David B., Settleman, Jeffrey, Shokat, Kevan M., Warren, Robert S.
Publicado 2013

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53

por Liu, Qi, Gheorghiu, Liliana, Drumm, Michael, Clayman, Rebecca, Eidelman, Alec, Wszolek, Matthew F., Olumi, Aria, Feldman, Adam, Wang, Meng, Marcar, Lynnette, Citrin, Deborah E., Wu, Chin-Lee, Benes, Cyril H., Efstathiou, Jason A., Willers, Henning
Publicado 2018

Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells

por Sun, Yang, Hu, Lu, Tao, Zhipeng, Jarugumilli, Gopala K., Erb, Hannah, Singh, Alka, Li, Qi, Cotton, Jennifer L., Greninger, Patricia, Egan, Regina K., Tony Ip, Y., Benes, Cyril H., Che, Jianwei, Mao, Junhao, Wu, Xu
Publicado 2022

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

por Choy, Edwin, Butrynski, James E, Harmon, David C, Morgan, Jeffrey A, George, Suzanne, Wagner, Andrew J, D’Adamo, David, Cote, Gregory M, Flamand, Yael, Benes, Cyril H, Haber, Daniel A, Baselga, Jose M, Demetri, George D
Publicado 2014

IFITM proteins assist cellular uptake of diverse linked chemotypes

por Lou, Kevin, Wassarman, Douglas R., Yang, Tangpo, Paung, YiTing, Zhang, Ziyang, O’Loughlin, Thomas A., Moore, Megan K., Egan, Regina K., Greninger, Patricia, Benes, Cyril H., Seeliger, Markus A., Taunton, Jack, Gilbert, Luke A., Shokat, Kevan M.
Publicado 2022

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations

por GALIMBERTI, FABRIZIO, BUSCH, ALEXANDER M., CHINYENGETERE, FADZAI, MA, TIAN, SEKULA, DAVID, MEMOLI, VINCENT A., DRAGNEV, KONSTANTIN H., LIU, FANG, JOHNSON, KEVIN C., GUO, YONGLI, FREEMANTLE, SARAH J., ANDREW, ANGELINE S., GRENINGER, PATRICIA, ROBBINS, DAVID J., SETTLEMAN, JEFF, BENES, CYRIL, DMITROVSKY, ETHAN
Publicado 2012

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

por Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Publicado 2015